The Broad Institute of MIT and Harvard is seeking an outstanding Postdoctoral Associate candidate to join the Priming Agent Team—an exciting multidisciplinary and multi-lab collaboration led by Viktor Adalsteinsson (Gerstner Center for Cancer Diagnostics at Broad), Sangeeta Bhatia (MIT), and J. Christopher Love (MIT)—that seeks to unlock the power of liquid biopsies for cancer diagnostics, by addressing critical biological bottlenecks. The goal of the Priming Agent Team is to develop the first diagnostic drugs for liquid biopsies that improve the recovery of circulating tumor DNA (ctDNA) to enable early cancer detection, monitoring for minimal residual disease, and minimally-invasive tumor genotyping from blood samples (see Martin-Alonso et al Science 2024). We are seeking an exceptionally motivated individual to pursue next generation strategies involving protein engineering, nanoparticle engineering, drug delivery, and/or synthetic biology approaches, to elucidate mechanisms of ctDNA shedding and develop pharmacologically-driven approaches to enable liquid biopsy cancer detection of otherwise low ctDNA-shedding tumors. Our team includes scientists, engineers, medical oncologists, and computational biologists, spanning the Broad Institute, MIT, Harvard, and Harvard-affiliated hospitals, and the successful candidate will gain exposure to cutting-edge science through meetings, symposia, and interactions with colleagues and collaborators.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree